SCHEMBL7062337

SCHEMBL7062337

CC(C)(C)ON(C=O)NCc1ccoc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
CNR2 P34972 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.32
ALOX5 P09917 1/20 0.32
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31
OPRK1 P41145 1/20 0.31
TSHR P16473 1/20 0.30
MCHR1 Q99705 1/20 0.30
USP2 O75604 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5373022 0.79 ADH1B (0.42) MEN1MAPTKMT2ATDP1
SCHEMBL7061205 0.77 RAB9A (0.40) ALDH1A1HTT
SCHEMBL5767016 0.75 MMP8 (0.39) ALDH1A1MEN1MAPTKMT2ATDP1
SCHEMBL7059655 0.74 TSHR (0.41) ALDH1A1MEN1MAPTRECQLKMT2A
SCHEMBL28754827 0.72 CETP (0.33) CNR2ALOX5SLC1A3SLC1A2SLC1A1
SCHEMBL7064438 0.72 CYP1A2 (0.49) ALDH1A1MEN1MAPTRECQLKMT2A
SCHEMBL5767277 0.71 ESR1 (0.41)
SCHEMBL6762362 0.68 RIPK1 (0.37) ALDH1A1MEN1KMT2AHPGDALOX5
SCHEMBL7061210 0.68 SMN1; SMN2 (0.42) ALDH1A1MEN1KMT2A
SCHEMBL7062957 0.67 CYP2A6 (0.50) FAAHMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162783-A1 Method and composition for the treatment of pain ASTRAZENECA AB (SE) 2003-08-28 US disclosed
EP-1248621-A1 METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2002-10-16 EP disclosed
WO-2001047523-A1 METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162783-A1 Method and composition for the treatment of pain OPRK1, OPRD1, ACHE FAAH 45/4885ALDH1A1 170/4885MEN1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.